BioNTech to Hold Digital Press Conference to Provide an Update on Omicron Variant

Rhea-AI Summary

BioNTech SE (Nasdaq: BNTX) has scheduled a digital press conference for December 8, 2021, at 3:00 PM CET to discuss initial laboratory study results regarding the impact of the Omicron variant on COVID-19 vaccine-induced immune responses. The conference will be conducted in English and streamed online, with no on-site attendance for journalists. Recordings and presentations will be available later on their website.

BioNTech is known for its development of mRNA-based therapies for cancer and infectious diseases, collaborating with various global pharmaceutical partners.

MAINZ, Germany, December 8, 2021 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will hold a digital press conference on Wednesday, December 8, 2021, to present the results from initial laboratory studies which started about two weeks ago. The studies aimed to investigate the effects of the Omicron variant on COVID-19 vaccine-induced immune responses. The press conference will solely be held in a virtual format and will be conducted in English.

International digital press conference at 3.00 pm CET / 9.00 am ET
Please register here.

The conference can be streamed. Interested journalists may dial in 10 to 15 minutes before the conference starts. They will be able to submit questions via an online tool.There will be no access for journalists on-site.

Participants may also digitally access the press conference on https://biontech.de/ under "Events & Presentations" in the Investor & Media section of the website. A recording of the press conference as well as the presentation will be available under the section “Past Events” on the same day.

About BioNTech
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bispecific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma and Pfizer.

For more information, please visit www.BioNTech.de

Media Relations
Jasmina Alatovic
+49 (0)6131 9084 1513
Media@biontech.de  

Investor Relations
Sylke Maas, Ph.D.
+49 (0)6131 9084 1074
Investors@biontech.de

FAQ

What is the purpose of BioNTech's press conference on December 8, 2021?

The press conference aims to present initial laboratory study results on the effects of the Omicron variant on COVID-19 vaccine-induced immune responses.

What time is the BioNTech press conference scheduled for?

The press conference is scheduled for December 8, 2021, at 3:00 PM CET (9:00 AM ET).

How can I access the BioNTech press conference?

You can register and attend the press conference online, which will also be streamed and accessible on BioNTech's website.

What type of studies is BioNTech presenting during the press conference?

BioNTech will present results from initial laboratory studies investigating the effects of the Omicron variant on vaccine-induced immune responses.